In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's New High-Risk Assessment Medtech Scheme Off To Slow Start

Executive Summary

Germany's new testing and treatment methods (NUBs) scheme for assessing benefit in high-risk products for inpatient use recently processed its first batch of applications. But, as with its longer-established outpatient products counterpart, it does not seem to be an instant success, says German reimbursement expert Ben Modley.

You may also be interested in...



Germany – Still Europe's Stand-Out Medtech Innovation Market

Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.

German Ambulatory Fast-Track Reimbursement Scheme Failing to Deliver

Germany’s system for fast-tracking selected, insufficiently proven ambulatory medtech products into commercial use seems to be falling short of its potential. This has set alarm bells ringing in an industry that is already concerned about its inpatient pass-through scheme (NUBs).

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel